Fundamentals of Biologicals Regulation
Vaccines and Biotechnology Medicines
- 2nd Edition - March 13, 2026
- Latest edition
- Authors: Rebecca Sheets, Christopher Hamlin, Susan Neadle, Ivana Knezevic, Mark Schenerman, Mehmet Tosun, Kathryn C. Zoon
- Language: English
This second edition of Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines serves as an introduction to the international regulatory arena in which biologi… Read more
World Book Day celebration
Where learning shapes lives
Up to 25% off trusted resources that support research, study, and discovery.
Description
Description
This second edition of Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines serves as an introduction to the international regulatory arena in which biologicals are developed and offers an overview of the processes and insight into the scientific concepts underpinning global regulations. In this new edition the book provides more in-depth coverage of Quality by Design, Combination Products, Quality Target Product Profiles, Risk Management Plans and REMS, and switching from reliance on in vivo to in vitro analytical methods. This new edition also reflects the new developments and processes accelerated by the COVID-19 vaccine experience, including emergency use authorizations and conditional marking authorizations. New pedagogic elements and case studies have been added to improve learning outcomes for students. This book provides multiple levels of readership with guidance on basic concepts, a detailed look at regulatory challenges, and practical insight into how regulators consider regulatory science and regulatory process issues across various regions with emphasis on the European Medicines Agency and the U.S. Food and Drug Administration. Graduate students will benefit from the new pedagogic features. Regulatory professionals will have in Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines a complete guide to navigate through the approval process.
Key features
Key features
• Presents new and updated case studies, including lessons learned from the development of COVID Vaccines
• More in-depth coverage on Quality by Design, Quality Target Product Profiles, and Pharmacovigilance
• Chapters focusing on the principles in regulating Biosimilars, In Vitro Diagnostics, Advanced Therapy Medicinal Products, and Combination Products
• Covers general biologicals development and authorization regulatory processes as well as scientific principles for CMC, preclinical and clinical development
• Also covers ethical considerations for use of laboratory animals and human subjects protections, as well as genetically modified organisms used in or as medicines
Readership
Readership
Graduate students or professionals studying regulatory affairs and regulatory science for a biology, biotechnology, or engineering Masters, Ph.D., or Certificate programs, Biologicals regulators in various countries who want to learn more about how other countries regulate similar products (particularly those in developing countries who want to learn about the US and EU processes). Developers of combination products or combined use systems (e.g., oncology products that are combined with a medical device).
Table of contents
Table of contents
Foreword
Preface
How to obtain documents from ICH and US
SECTION I: Regulatory process
1 Introduction to the regulatory process for biologicals and to international regulatory convergence2 Discovery and development
3 Communications and formal meetings with regulators
4 Clinical trial authorization and investigational new drug applications
5 Marketing authorization
6 Alternative regulatory pathways and special programs
7 Variations or changes to an approved application
8 Good “X” Practices
9 Audits and regulatory compliance inspections
Written assignments exercise
Assignment Scenarios
SECTION II: Regulatory science
10 Preclinical safety and toxicology11 Preclinical pharmacology, proof‑of‑principle
12 Institutional biosafety committees and regulation of genetically modified organisms
13 Risk assessments
14 Quality by design and product design, construction, development, manufacture, and process validation
15 Lot release, analytics, and analytical validation
16 Regulatory aspects of clinical trials
17 Pharmacovigilance, safety reporting, and risk minimization
18 Clinical trial ethics, human subjects protections, and the informed consent process
19 Independent ethics committees and institutional review boards
SECTION III: Specific product types
20 Biosimilars21 Cell and gene therapies
22 In vitro diagnostics and biotech medical devices
23 Combination products
Glossary
Index
Product details
Product details
- Edition: 2
- Latest edition
- Published: March 13, 2026
- Language: English
About the authors
About the authors
RS
Rebecca Sheets
CH
Christopher Hamlin
SN
Susan Neadle
Dr. Susan Neadle is a recognized international Combination Products, Medical Device, and Digital Health expert with over 35 years industry experience. She is well networked, published, and highly active in numerous industry groups with links to teaching institutions. Neadle’s leadership, innovation, and best practices have been recognized with multiple awards, including the Johnson Medal, Johnson & Johnson’s highest honor for excellence in Research & Development, and most recently, as a Finalist in TOPRA’s 2021 Awards for Regulatory Affairs Excellence. Neadle retired from a distinguished and impactful 26-year career at Johnson & Johnson. She is now Principal Consultant at Combination Products Consulting Services LLC, providing international Q&C, regulatory and design excellence services, to the pharm, biotech and device industries. Neadle serves as Chair of the ISPE Combination Products CoP, and Lead Author in Combination Products Working Groups through ASTM International, AAMI and PQRI. She teaches curricula in Combination Products through UMBC and AAMI, as well as customized training upon request.
IK
Ivana Knezevic
Dr. Ivana Knezevic, MD, PhD Scientist, Technologies, Standards and Norms Team, Group Lead, Norms and Standards for Biologicals, Department of Essential Medicines and Health Products (EMP), Health Systems and Innovation (HIS) Cluster, World Health Organization (WHO), Switzerland. She is a specialist in medical microbiology and parasitology. She received her MD from the University of Novi Sad, MSc in medicine (microbiology) and PhD in medicine (virology) from the University of Belgrade, Republic of Serbia. Ivana Knezevic has 24 years of professional experience in standardization, scientific and regulatory overview of biologicals. Dr. Knezevic is the author of many publications that made broad audience aware of WHO initiative in the development, establishment, and implementation of standards for vaccines and biotherapeutic products. She is also contributing to the peer-review scientific journals with the international reputation.
MS
Mark Schenerman
MT
Mehmet Tosun
Dr. Mehmet Tosun is a physician-scientist with over 15 years of experience in clinical trials and research endeavors. He is an adjunct faculty member in the Biotechnology Program at the University of Maryland, Baltimore County. He served as the Director of Research to develop mRNA-based cell therapy for autoimmune diseases, rare disease and cancers in a clinical-stage biotechnology company in Gaithersburg, Maryland.
He worked as a Project Scientist in tissue engineering group to develop biomaterials for the repair of visceral hollow organs at University of California, Irvine, School of Medicine. He joined the team to identify the systems-level machinery governing vertebral segmentation during embryonic development at Albert Einstein College of Medicine, Department of Genetics. He completed his postdoctoral fellowship at Baylor College of Medicine, Department of Pediatrics at Texas Children Hospital. He specifically focused on neuronal stem cells resides in hippocampus to explain the adult neurogenesis mechanism. He developed a unique method to characterize the complex lipid features of the different parts of the brain. He has expertise in clinical drug development, translational clinical research, immunotherapy, and clinical data monitoring.
KZ
Kathryn C. Zoon
Dr. Kathryn C. Zoon is a U.S.-based immunologist, elected to the U.S. Institute of Medicine in 2002 for her research on human interferons and administrative public health contributions. She is the former scientific director of the Division of Intramural Research at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) in Bethesda, Maryland (2006-2015). From 1992 to 2002, Dr. Zoon was director of the FDA Center for Biologics Evaluation and Research (CBER). She is currently Scientist Emerita, NIH and on the Board of Directors of Emergent Biosolutions, Inc. and the International Biomedical Research Alliance. Dr. Zoon obtained her B.S. cum laude from Rensselaer Polytechnic Institute in 1970 and her Ph.D. in biochemistry from Johns Hopkins University in 1976. Soon after receiving her Ph.D., she undertook a training fellowship in the NIH laboratory of Christian B. Anfinsen, who had won the 1972 Nobel Prize in Chemistry.